Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Gut 64.6 (2015): S. 973-981.
- Keyword
-
-
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2015
- Creator
-
Arndt, Stephanie
Wacker, Eva
Dorn, Christoph
Koch, Andreas
Saugspier, Michael
Thasler, Wolfgang E.
Hartmann, Arndt
Bosserhoff, Anja Katrin
Hellerbrand, Claus
- URN
-
urn:nbn:de:bvb:29-opus4-81534
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:44 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Arndt, Stephanie
- Wacker, Eva
- Dorn, Christoph
- Koch, Andreas
- Saugspier, Michael
- Thasler, Wolfgang E.
- Hartmann, Arndt
- Bosserhoff, Anja Katrin
- Hellerbrand, Claus
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2015
Other Objects (12)
Analysis of non-alcoholic beverages
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
The sspecific NLRP3 antagonist IFM-514 decreases fibrosis and inflammation in experimental murine non-alcoholic steatohepatitis
The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Differential lipidomics, metabolomics and immunological analysis of alcoholic and non-alcoholic steatohepatitis in mice
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression
Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of non-alcoholic steatohepatitis and biliary fibrosis
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis
Analysis of non-alcoholic beverages
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
The sspecific NLRP3 antagonist IFM-514 decreases fibrosis and inflammation in experimental murine non-alcoholic steatohepatitis
The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Differential lipidomics, metabolomics and immunological analysis of alcoholic and non-alcoholic steatohepatitis in mice
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression
Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of non-alcoholic steatohepatitis and biliary fibrosis
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis
Analysis of non-alcoholic beverages
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
The sspecific NLRP3 antagonist IFM-514 decreases fibrosis and inflammation in experimental murine non-alcoholic steatohepatitis
The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Differential lipidomics, metabolomics and immunological analysis of alcoholic and non-alcoholic steatohepatitis in mice
The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression
Dipeptidyl peptidase 4 inhibitors and glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of non-alcoholic steatohepatitis and biliary fibrosis
Murine one-carbon metabolism in non-alcoholic fatty liver disease
Murine one-carbon metabolism in non-alcoholic fatty liver disease